Recent Finacing
Recent Raise
Ixchelsis is a clinical-stage UK biotechnology company developing IX-01, an oxytocin receptor antagonist for premature ejaculation, collaborating with Lilly’s Chorus to advance the compound to human proof-of-concept.
Focus Areas
Recent Investors
Funding round
Investor